Report Overview

Indian Hemophilia A market size stood at around USD xx billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Hemophilia A is one of the X chromosome-linked genetic disorder which is caused by the mutations in the genes for factor VIII (FVIII). It has a clotting factor, which is a part of the intrinsic pathway of blood coagulation. Hemophilia A usually characterized by an immediate or delayed bleeding or prolonged injuries, tooth extractions, surgery, bleeding once initial bleeding has stopped. Around 30% of severe Hemophilia A patients develops neutralizing anti-FVIII alloantibodies (inhibitors), which may renders the FVIII replacement ineffective. Till now, there is no evident cure for hemophilia A and treatments are majorly concentrated on the management of the disease.



Market Drivers

The market drivers for the Hemophilia A are the development of novel treatments, popularity of gene therapy, increased focus on prophylactic treatment. Availability of limited treatment therapy options and the growing burden on the regulatory bodies towards its treatment results in increasing R&D efforts. In addition, rising awareness campaigns and supportive initiatives plan by the government to commence early screening of neonates, which is expected to boost the requirement of diagnostic tools related to Hemophilia A.